Stock VACC NYKODE THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News Nykode Therapeutics

Equities

VACC

NO0010714785

Market Closed - Oslo Bors
Other stock markets
 15:45:00 26/04/2024 BST 		5-day change 1st Jan Change
12.98 NOK 0.00% Intraday chart for Nykode Therapeutics +0.15% -39.35%
04-19 Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine MT
04-19 Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine
MT
Nykode Therapeutics : Remuneration Report 2023
PU
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
CI
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
CI
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases
CI
Transcript : Nykode Therapeutics AS, Q4 2023 Earnings Call, Feb 28, 2024
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Nykode Therapeutics AS Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer
CI
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Transcript : Nykode Therapeutics AS, Q3 2023 Earnings Call, Nov 15, 2023
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
AQ
Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding
CI
Nykode Therapeutics AS announced that it expects to receive NOK 329.999987 million in funding
CI
Nykode Therapeutics Kicks off Early-stage Trial of Head, Neck Skin Cancer Treatment
MT
Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer
CI
Transcript : Nykode Therapeutics AS - Analyst/Investor Day
Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research
CI
Nykode Therapeutics Wins US FDA Nod for Mid-stage Study of Cervical Cancer Combo
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VACC Stock
  4. News Nykode Therapeutics